A point worth emphasizing is that THL and other small-molecule inhibitors 55-57 targeting PSMD14 should not be completely equated with proteasome inhibitor which is an effective therapy for patients with multiple myeloma 58, 59, because of the dual role of their target PSMD14 in determining substrates fate. This evidence concerns the gene PSMD14 and plasma cell myeloma.